DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients.

Diagn Pathol · 2023 · PMC10623851 · PMID 37924135

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among all NSCLC patients receiving platinum-based chemotherapy, DDR-positive patients showed a trend towards better PFS, with no significant difference (Fig. 4 A).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.